Clinical Trial

MASKd: a Study on Kawasaki Disease (KD) Complicated by Macrophage Activation Syndrome (MAS)

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Kawasaki Disease (KD) is one of the most common vasculitides in childhood and represents a leading cause of acquired heart disease in developed countries. Macrophage Activation Syndrome (MAS) is a potentially life threatening hyperinflammatory condition belonging to the spectrum of hemophagocytic lymphohistiocytosis (HLH), and it can complicate various rheumatologic diseases. Awareness of MAS in the context of KD has recently increased, supporting the hypothesis that it is an underdiagnosed complication. The study aims to define the epidemiology, clinical characteristics, management, and therapeutic strategies of MAS in patients with KD, through a multicenter data collection in Europe.
Trial Details
NCT Number NCT07491926
Lead Sponsor Meyer Children's Hospital IRCCS
Conditions Kawasaki Disease, Macrophage Activation Syndrome (MAS)
Enrollment 150 participants
Start Date 2026-02
Primary Completion 2027-11 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-25